Novo Nordisk A/S (NYSE:NVO - Get Free Report) shares dropped 1.6% on Thursday . The company traded as low as $58.45 and last traded at $58.64. Approximately 8,796,369 shares traded hands during mid-day trading, a decline of 28% from the average daily volume of 12,145,591 shares. The stock had previously closed at $59.61.
Wall Street Analyst Weigh In
NVO has been the topic of a number of recent analyst reports. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a "neutral" rating to a "buy" rating in a research note on Tuesday, September 16th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Novo Nordisk A/S in a research note on Saturday, September 27th. Berenberg Bank raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Wednesday, September 17th. Rothschild Redb raised shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 16th. Finally, HSBC set a $70.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Moderate Buy" and a consensus price target of $77.50.
Get Our Latest Report on NVO
Novo Nordisk A/S Price Performance
The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The stock has a market cap of $261.83 billion, a P/E ratio of 16.11, a PEG ratio of 2.70 and a beta of 0.68. The firm's fifty day moving average price is $55.26 and its 200-day moving average price is $63.33.
Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The firm had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.
Novo Nordisk A/S Cuts Dividend
The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were issued a $0.4119 dividend. The ex-dividend date was Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 22.53%.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the company. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares in the last quarter. North Capital Inc. bought a new stake in Novo Nordisk A/S in the first quarter valued at $27,000. Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S in the first quarter valued at $30,000. NewSquare Capital LLC boosted its holdings in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company's stock valued at $31,000 after acquiring an additional 282 shares in the last quarter. Finally, Disciplina Capital Management LLC boosted its holdings in Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after acquiring an additional 297 shares in the last quarter. Institutional investors own 11.54% of the company's stock.
About Novo Nordisk A/S
(
Get Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
